Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
Mayo Clinic
Mayo Clinic
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Roswell Park Cancer Institute
First Affiliated Hospital of Zhejiang University
Stanford University
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
University of Chicago
Hackensack Meridian Health